Astellas Pharma Inc.
【Astellas Pharma】2026-2030 Growth Strategy and New Management Plan｜May 2026
Astellas Pharma is formulating a management plan for 2026 to 2030, aiming to double sales of key strategic products and increase research and development investments, targeting record-high sales revenues by the mid-2030s.
Key Figures
- Core operating profit before R&D tax credits: Over 4.3 trillion yen
- Sales of key strategic products: 2x (FY2025 comparison)
- Number of Phase III / Pivotal Trials Started: Over 10
AI要約
Performance Overview
Astellas Pharma has developed a management plan covering FY2026 to FY2030, with plans to double the sales of key strategic products and strengthen R&D investments. The company aims to achieve record-high sales revenues by the mid-2030s, targeting the start of over 10 Phase III / Pivotal Trials and generating core operating profit before R&D tax credits of over 4.3 trillion yen. To balance profitability and growth, they are focused on cost optimization and productivity improvements.
Future Outlook and Shareholder Returns
Astellas Pharma aims to achieve record-high sales revenues by 2030 through growth in key strategic products and pipeline expansion. By investing in R&D and maintaining disciplined cash allocation, the company plans to realize sustainable growth and continue increasing dividends by at least 2 yen annually. Organizational reforms and productivity enhancements are promoted to maximize patient value and increase corporate value.
Astellas Pharma Inc.
Company overview · Stock price · Financial data · All IR
